UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 686

Sortiert nach

External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer

Annals of oncology, 2012-02, Vol.23 (2), p.361-367

2012

Volltextzugriff (PDF)

A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data

Annals of oncology, 2018-10, Vol.29, p.viii206-viii206

2018

Volltextzugriff (PDF)

A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)

Annals of oncology, 2017-09, Vol.28, p.v209-v209

2017

Volltextzugriff (PDF)

2317 Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab

European journal of cancer (1990), 2015-09, Vol.51, p.S438-S438

2015

Volltextzugriff (PDF)

44 Metformin and its impact on gastric cancer patients survival after gastrectomy

European journal of cancer (1990), 2014-11, Vol.50, p.20-20

2014

Volltextzugriff (PDF)

2364 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib trial

European journal of cancer (1990), 2015-09, Vol.51, p.S457-S457

2015

Volltextzugriff (PDF)

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

European journal of cancer (1990), 2015-09, Vol.51, p.S446-S446

2015

Volltextzugriff (PDF)

049 Preventing sexually transmitted infection from hookups in Taiwan

Journal of sexual medicine, 2018-07, Vol.15 (7), p.S145-S145

2018

Volltextzugriff (PDF)

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Annals of oncology, 2022-02, Vol.33 (2), p.169-180

2022

Volltextzugriff (PDF)

Individualization of Breast Cancer Treatment: Opportunities and Challenges in Asia

Annals of oncology, 2012-10, Vol.23, p.xi89-xi90

Chung, H.C.

2012

Volltextzugriff (PDF)

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Annals of oncology, 2019-02, Vol.30 (2), p.250-258

2019

Volltextzugriff (PDF)

Glioma Tropic Neural Stem Cells Consist of Astrocytic Precursors and Their Migratory Capacity Is Mediated by CXCR4

Neoplasia (New York, N.Y.), 2004-05, Vol.6 (3), p.287-293

2004

Volltextzugriff (PDF)

6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma – a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG)

European journal of cancer (1990), 2011, Vol.47, p.S470-S471

2011

Volltextzugriff (PDF)

5058 POSTER Randomized Phase II Multicenter Trial of Oral Antiangiogenic Agent TSU-68 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline

European journal of cancer (1990), 2011, Vol.47, p.S347-S347

2011

Volltextzugriff (PDF)

Determination of piezoelectric coefficients and elastic constant of thin films by laser scanning vibrometry techniques

Sensors and actuators. A. Physical., 2007-04, Vol.135 (2), p.660-665

2007

Volltextzugriff (PDF)

1246P Multicenter phase Ib/II study of second-line varlitinib and paclitaxel in patients with EGFR/HER2 co-expressing advanced gastric cancer (K-MASTER-13)

Annals of oncology, 2022-09, Vol.33, p.S1118

2022

Volltextzugriff (PDF)

3032 POSTER Health-related Quality of Life in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Cancer With High HER2 Expression Levels – Exploratory Analysis of the Phase III ToGA Study

European journal of cancer (1990), 2011, Vol.47, p.S231-S232

2011

Volltextzugriff (PDF)

UP-2.02: The Effect of Tamsulosin in Female Patients with Lower Urinary Tract Symptoms and Predictive Factors for Therapeutic Outcome: Multicenter, Prospective Study

Urology (Ridgewood, N.J.), 2010, Vol.76 (3), p.S80-S80

2010

Volltextzugriff (PDF)

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Annals of oncology, 2021-09, Vol.32 (9), p.1127-1136

2021

Volltextzugriff (PDF)

131 JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IS WELL-TOLERATED AND EXHIBITS ANTI-TUMOR ACTIVITY IN PATIENTS WITH PRIMARY LIVER CANCER AND LIVER METASTASES

Journal of hepatology, 2011-03, Vol.54, p.S58-S58

2011

Volltextzugriff (PDF)

124 RANDOMIZED PHASE II CLINICAL TRIAL OF INTRATUMORAL INJECTION OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Journal of hepatology, 2010, Vol.52, p.S55-S55

2010

Volltextzugriff (PDF)

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

European journal of cancer (1990), 2019-02, Vol.108, p.17-24

2019

Volltextzugriff (PDF)

1577P Prior antibiotic administration disrupts outcomes of PD-1 blockade in advanced gastric cancer by altering gut microbiome and systemic immune response

Annals of oncology, 2023-10, Vol.34, p.S880-S880

2023

Volltextzugriff (PDF)

P-02-51 Add-On Treatment With Mirabegron in Men With Benign Prostatic Hyperplasia Complaining Persistent Storage Symtoms after Tamsulosin Monotherapy Improves Quality of Life

Journal of sexual medicine, 2020-06, Vol.17 (6), p.S188-S188

2020

Volltextzugriff (PDF)

1382P Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer

Annals of oncology, 2021-09, Vol.32, p.S1047-S1047

2021

Volltextzugriff (PDF)

1 – 25 von 686

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(578)
Mit Volltextzugriff
(647)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(399)
Life Sciences & Biomedicine
(263)
Technology
(124)
Humans
(120)
Biological And Medical Sciences
(97)
Engineering
(80)
Male
(75)
Animals
(69)
Female
(68)
Exact Sciences And Technology
(63)
Physical Sciences
(62)
Fundamental And Applied Biological Sciences. Psychology
(50)
Medical Sciences
(50)
Biochemistry & Molecular Biology
(47)
Physics
(47)
Engineering, Electrical & Electronic
(44)
Middle Aged
(41)
Adult
(39)
Aged
(38)
Chemistry
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer

A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data

A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)

2317 Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab

44 Metformin and its impact on gastric cancer patients survival after gastrectomy

2364 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib trial

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

049 Preventing sexually transmitted infection from hookups in Taiwan

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Individualization of Breast Cancer Treatment: Opportunities and Challenges in Asia

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Glioma Tropic Neural Stem Cells Consist of Astrocytic Precursors and Their Migratory Capacity Is Mediated by CXCR4

6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma – a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG)

5058 POSTER Randomized Phase II Multicenter Trial of Oral Antiangiogenic Agent TSU-68 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline

Determination of piezoelectric coefficients and elastic constant of thin films by laser scanning vibrometry techniques

1246P Multicenter phase Ib/II study of second-line varlitinib and paclitaxel in patients with EGFR/HER2 co-expressing advanced gastric cancer (K-MASTER-13)

3032 POSTER Health-related Quality of Life in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Cancer With High HER2 Expression Levels – Exploratory Analysis of the Phase III ToGA Study

UP-2.02: The Effect of Tamsulosin in Female Patients with Lower Urinary Tract Symptoms and Predictive Factors for Therapeutic Outcome: Multicenter, Prospective Study

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

131 JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IS WELL-TOLERATED AND EXHIBITS ANTI-TUMOR ACTIVITY IN PATIENTS WITH PRIMARY LIVER CANCER AND LIVER METASTASES

124 RANDOMIZED PHASE II CLINICAL TRIAL OF INTRATUMORAL INJECTION OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

1577P Prior antibiotic administration disrupts outcomes of PD-1 blockade in advanced gastric cancer by altering gut microbiome and systemic immune response

P-02-51 Add-On Treatment With Mirabegron in Men With Benign Prostatic Hyperplasia Complaining Persistent Storage Symtoms after Tamsulosin Monotherapy Improves Quality of Life

1382P Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer

Suchergebnisse filtern